GRI Bio, Inc. (GRI) NASDAQ
2.54
-0.36(-12.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.54
-0.36(-12.41%)
Currency In USD
| Previous Close | 2.9 |
| Open | 2.88 |
| Day High | 2.93 |
| Day Low | 2.52 |
| 52-Week High | 311.36 |
| 52-Week Low | 2.1 |
| Volume | 61,251 |
| Average Volume | 401,272 |
| Market Cap | 228,173 |
| PE | -0.02 |
| EPS | -121.8 |
| Moving Average 50 Days | 4.2 |
| Moving Average 200 Days | 34.08 |
| Change | -0.36 |
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GlobeNewswire Inc.
Feb 17, 2026 2:15 PM GMT
Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
GlobeNewswire Inc.
Feb 05, 2026 2:15 PM GMT
– Live video webcast on Wednesday, February 11th at 1:00 PM EST LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modul
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
GlobeNewswire Inc.
Feb 04, 2026 1:45 PM GMT
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-062